Antiretroviral therapy (ART) inhibits the enzymatic function of viral proteins or blocks viral entry but does not inhibit HIV-1 LTR promoter activity. The HIV-1 LTR remains functional and active despite effective ART. Around 1–64 per million CD4+ T cells contain replication-competent HIV-1 proviruses. HIV-1 LTR drives the expression of intact HIV-1 proviruses, leading to viral rebound upon treatment interruptions. Around 100–1000 per million CD4+ T cells contain replication-defective HIV-1 proviruses. These replication-defective HIV-1 proviruses can be transcribed and translated, leading to antigen presentation to CD8+ T cells and immune distraction. Meanwhile, cells harboring intact and defective HIV-1 proviruses can both undergo clonal expansion, and the clonally expanded cells increase over time. HIV-1 integration site analysis revealed striking enrichment of HIV-1 integration at specific sites of proliferation-related genes in the clonally expanded cells, but the mechanisms remain unknown. The rarity and the lack of cellular markers of HIV-1-infected cells makes mechanistic studies challenging. Using single-cell RNAseq and high-resolution RNA landscape mapping on CD4+ T cells from virally suppressed, HIV-1-infected individuals, we show that HIV-1 LTR dominates over the host promoter and drives the host gene expression at the integration sites in genes associated with in vivo clonal expansion. HIV-1 activates cryptic host gene splice sites and induces aberrant host gene transcription, while HIV-1 viral genome transcription remains intact. Overall, HIV-1 LTR drives viral and host gene expression at the same time. Strategies targeting HIV-1 LTR should be explored to disrupt HIV-1-induced immune activation and HIV-1-driven aberrant proliferation gene expression.